Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PISTIAS-3
NCT07466251Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Sep 2026
- Primary completion
- Dec 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of recaticimab in ischemic stroke, intracranial atherosclerosis (ICAD), sponsored by Peking Union Medical College Hospital. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
recaticimab
03
Conditions
ischemic strokeintracranial atherosclerosis (ICAD)
Beyond the preview
Go deeper on NCT07466251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07466251.